Nu Skin Q3 2026 Earnings: Core Revenue Decline Compresses Margins

Nu Skin Enterprises (NYSE: NUS) reported Q3 2026 revenue of $311.0 million, down 14.6% from $364.2 million, while diluted EPS moved to a loss of $0.02 from earnings of $0.34. Adjusted EPS was $0.10, with declining customers and sales participants weighing on the core Nu Skin business even as Rhyz manufacturing expanded.

Core Earnings Data

Revenue was within the company’s guidance range but fell 13.5% on a constant-currency basis. Foreign exchange reduced reported revenue by $3.9 million, or 1.1 percentage points.

Profit contracted faster than revenue. Gross margin declined by 5.5 percentage points, while adjusted operating margin fell to 3.7% even after excluding $6.3 million of specified charges.

Adjusted results exclude severance, professional fees, and other specified items.

Rhyz Growth Could Not Offset Core Nu Skin Contraction

Core Nu Skin revenue fell 19.2% to $252.6 million, including declines in every major geographic market. Rhyz revenue increased 13.2% to $58.4 million, but its approximately $6.8 million increase was not enough to offset the roughly $60.0 million decline in Nu Skin revenue.

Rhyz manufacturing was the growth driver, with revenue rising 19.3% to $56.8 million. Within Nu Skin, South Korea recorded the steepest reported decline at 30.7%, followed by Europe and Africa at 26.6% and Southeast Asia/Pacific at 23.5%.

The operating indicators behind Nu Skin’s revenue also weakened. Customers declined 18% to 609,469, paid affiliates fell 10% to 116,449, and sales leaders decreased 13% to 26,995. These declines were broad-based rather than concentrated in a single market.

Margin Compression and Taxes Erased Most Operating Profit

Consolidated gross margin fell to 65.0%, while the Nu Skin business’s gross margin declined more moderately to 76.6% from 77.7%. Rhyz manufacturing grew while Nu Skin contracted, increasing Rhyz’s share of consolidated revenue; the company did not quantify how much this change in business mix affected gross margin.

Selling expenses declined to $103.2 million from $130.3 million and improved to 33.2% of revenue from 35.8%. General and administrative expenses also decreased in dollars, to $93.9 million from $104.8 million, but rose to 30.2% of revenue from 28.8% because revenue declined faster.

The quarter included $6.3 million of other charges, consisting primarily of $5.1 million in employee severance and $1.2 million in professional fees. Excluding these items, operating margin was still lower at 3.7% compared with 5.9% a year earlier.

A $2.6 million tax provision exceeded pretax income of $1.9 million, producing a GAAP net loss of $742,000. The reported effective tax rate was 139.3%, compared with an adjusted rate of 42.7%.

Balance Sheet and Capital Allocation

Cash and cash equivalents declined to $164.9 million at September 30 from $238.6 million at the end of 2025. Over the same period, inventory increased to $191.7 million from $178.6 million, while accounts receivable rose to $51.4 million from $39.5 million.

Long-term debt decreased to $183.7 million from $204.2 million, with another $20.0 million classified as current debt. Nu Skin paid $2.9 million in dividends during the quarter and completed no share repurchases, leaving $137.3 million under its existing authorization.

Earnings Guidance

Nu Skin projected another year-over-year revenue decline in Q4, although management said it expects sequential growth. The midpoint of the Q4 range is $325 million, approximately 4.5% above Q3 revenue, while the lower end is roughly flat sequentially.

The company expects approximately $5.0 million of cash-based transition costs in Q4. The wide gap between full-year GAAP and adjusted EPS also reflects impairment charges and a valuation allowance on deferred tax assets recorded during the year.

Management View

CEO Ryan Napierski described the operating environment as challenging and said the company is focusing on affiliate and customer engagement during the holiday season. Management highlighted continued adoption of the Prysm iO platform, year-to-date revenue growth for LifePak nutritional supplements, and upcoming anti-aging offerings focused on women’s health, although it did not quantify their expected revenue contribution.

Recent Insider Transactions

Reported insider data for the latest six-month period show net purchases of 169,460 shares across 12 transactions. However, eight of the latest 10 individual entries were director stock awards and two were sales, so the aggregate purchase figure should not be interpreted as entirely open-market buying.

Risks Investors Need to Watch

• Continued contraction in the core sales network: Customers, paid affiliates, and sales leaders all declined, creating pressure on future Nu Skin product demand.
• Persistent margin pressure: Adjusted operating margin declined even after excluding specified charges, indicating that lower revenue and gross margin are affecting underlying profitability.
• Limited near-term revenue recovery: Q4 guidance still implies an 8% to 16% year-over-year decline, and its lower end is roughly flat with Q3.
• Cash and inventory trends: Cash declined while inventory increased despite lower revenue, making inventory management and cash conversion important areas to monitor.
• Tax and restructuring volatility: The high reported tax rate, severance costs, transition spending, impairment charges, and deferred-tax valuation allowance create a substantial difference between GAAP and adjusted results.

Summary

Nu Skin’s Q3 2026 results showed a broad contraction in its core business, with falling customer and sales-participant counts contributing to lower revenue and margins. Rhyz manufacturing provided growth but remained too small to offset Nu Skin’s decline. The main indicators for coming quarters are whether holiday engagement and new product initiatives can stabilize core demand, whether margins recover as restructuring continues, and whether cash and inventory trends improve.